Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro

被引:57
作者
Hansen, JB
Huseby, KR
Huseby, NE
Ezban, M
Nordoy, A
机构
[1] UNIV TROMSO,INST MED BIOL,DEPT CLIN CHEM,N-9037 TROMSO,NORWAY
[2] NOVO NORDISK AS,DIV HLTH CARE,DK-2820 GENTOFTE,DENMARK
关键词
TFPI; LDL; anticoagulant function; western blotting;
D O I
10.1016/S0049-3848(97)00029-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of the extrinsic coagulation system. In human plasma 70-85% is associated with apoB-containing lipoproteins whereas 10-20% exists in a carrier free form. The purpose of the present study was to assess the anticoagulant function of TFPI in complex with low density lipoproteins (LDL) on tissue factor (TF)-induced coagulation in vitro. LDL-TFPI complexes were isolated by preparative density gradient ultracentrifugation, LDL-free TFPI by preparative gel filtration and the anticoagulant properties were assessed by a diluted prothrombin time assay(dPT). LDL-free TFPI (0-0.46 U/ml) added to the dPT mixture, caused a prominent dose-dependent prolongation of dPT (0-42.2 sec.) which could be abolished by the addition of blocking anti-TFPI IgG. Contrary, increasing amounts of LDL-bound TFPI (0-4.0 U/ml) shortened dPT by 11.4 sec at the highest concentration. LDL-bound TFPI was not immunodetected by anti-TFPI IgG directed against the distal portion of the C-terminus, and appeared on Western blotting with a major band at 67 kDa and a weak band at 34 kDa which suggest that LDL-bound TFPI lack anticoagulant function due to carboxy terminal truncation. Our data provide evidence for the hypothesis that the anticoagulant function of TFPI is restricted to its carrier free form in human plasma. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:413 / 425
页数:13
相关论文
共 39 条
  • [1] RESPONSE OF PLASMA TISSUE FACTOR PATHWAY INHIBITOR TO DIET-INDUCED HYPERCHOLESTEROLEMIA IN CRAB-EATING MONKEYS
    ABUMIYA, T
    NAKAMURA, S
    TAKENAKA, A
    TAKENAKA, O
    YOSHIKUNI, Y
    MIYAMOTO, S
    KIMURA, T
    ENJYOJI, K
    KATO, H
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (03): : 483 - 488
  • [2] AN ANTITISSUE FACTOR PATHWAY INHIBITOR (TFPI) MONOCLONAL-ANTIBODY RECOGNIZED THE 3RD KUNITZ DOMAIN (K3) OF FREE-FORM TFPI BUT NOT LIPOPROTEIN-ASSOCIATED FORMS IN PLASMA
    ABUMIYA, T
    ENJYOJI, K
    KOKAWA, T
    KAMIKUBO, Y
    KATO, H
    [J]. JOURNAL OF BIOCHEMISTRY, 1995, 118 (01) : 178 - 182
  • [3] BROZE GJ, 1994, BLOOD COAGUL FIBRIN, V5, P551
  • [4] BROZE GJ, 1988, BLOOD, V71, P335
  • [5] DAVIES MJ, 1993, BRIT HEART J, V69, pS3
  • [6] ELSAADANI M, 1989, J LIPID RES, V30, P627
  • [7] BLOCKING OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) SHORTENS THE BLEEDING-TIME IN RABBITS WITH ANTIBODY-INDUCED HEMOPHILIA-A
    ERHARDTSEN, E
    EZBAN, M
    MADSEN, MT
    DINESS, V
    GLAZER, S
    HEDNER, U
    NORDFANG, O
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1995, 6 (05) : 388 - 394
  • [8] FUNCTIONAL-SIGNIFICANCE OF THE KUNITZ-TYPE INHIBITORY DOMAINS OF LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR
    GIRARD, TJ
    WARREN, LA
    NOVOTNY, WF
    LIKERT, KM
    BROWN, SG
    MILETICH, JP
    BROZE, GJ
    [J]. NATURE, 1989, 338 (6215) : 518 - 520
  • [9] TISSUE-FACTOR PATHWAY INHIBITOR AND LIPOPROTEINS - EVIDENCE FOR ASSOCIATION WITH AND REGULATION BY LDL IN HUMAN PLASMA
    HANSEN, JB
    HUSEBY, NE
    SANDSET, PM
    SVENSSON, B
    LYNGMO, V
    NORDOY, A
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1994, 14 (02): : 223 - 229
  • [10] EFFECT OF CHOLESTEROL-LOWERING ON INTRAVASCULAR POOLS OF TFPI AND ITS ANTICOAGULANT POTENTIAL IN TYPE-II HYPERLIPOPROTEINEMIA
    HANSEN, JB
    HUSEBY, KR
    HUSEBY, NE
    SANDSET, PM
    HANSSEN, TA
    NORDOY, A
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) : 879 - 885